Rubbing my ball, page-436

As well as Morningstar now covering IMU, the article below was posted on Nabtrade website yesterday. IMU was the first of 6 biotechs. More positive publicity- helping getting the message out there on a major share trading platform.

Great day! Remember I’m Eugene and have a Jim Beam (newbies check out the video).

PDS


SIX BIOTECH STARS By James DunnTue 10 November 2020 01:21 PM Share

Recent articlesThe biotech sector can be a minefield for investors, but the returns can be spectacular for the investor that accepts the fact that there is a long pathway between the laboratory and the market – and that pathway is fraught with potential mis-steps.The sector grabs a lot of investor attention because in many cases the companies are trying to commercialise world-leading scientific advances – often made here in Australia.Here are 6 fascinating examples of exciting potential biotech breakthroughs on the ASX.

1. Imugene (IMU:ASX)Market capitalisation: $284 millionThree-year total return: +44.7% a yearImugene works in immuno-oncology, the anti-cancer field in which the body’s immune system is artificially stimulated to boost its natural ability to fight the disease (sometimes called “cancer immuno-therapy.”) Imugene is developing four new treatments that activate the immune system of cancer patients to identify and eradicate tumours.Earlier this month, Imugene received approval from the US Food and Drug Administration (FDA) to begin a clinical trial in the US for its PD1-Vaxx drug – IMU gained Investigational New Drug (IND) approval to begin enrolment in a Phase 1 trial in patients with non-small cell lung cancer, or NSCLC (the most common type of lung cancer, accounting for about 80% of cases.) PD1-Vaxx, one of Imugene’s portfolio of B-cell immunotherapy candidates, is already in clinical trials in Australia. B cells are one of the influences on whether patients respond to immunotherapy in a variety of cancers.Imugene’s HER-Vaxx candidate, which is a B-cell peptide cancer immunotherapy designed to treat tumours in gastric, breast, ovarian, lung and pancreatic cancers, is also in Phase 2 trials in gastric cancer patients.The company is also working in the highly promising area of oncolytic virotherapy, a form of cancer treatment that uses naturally occurring or genetically modified viruses to infect, replicate in, and kill cancer cells, while sparing healthy cells. Imugene’s two oncolytic virotherapies, VAXinia and CHECKvacc, are also planned to start Phase 1 trials in the near future. VAXinia will be tested in a patient population including those suffering from advanced or metastatic melanoma, non-small cell lung, gastric, colorectal, Triple Negative Breast Cancer (TNBC), bladder, head and neck and renal cell cancers. Pre-clinical studies of CHECKvacc have shown particularly encouraging results in triple negative breast cancer (TNBC).